News | Pharmaceuticals | January 10, 2019

Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall

Recall initiated due to trace amounts of an impurity classified as a probable human carcinogen

Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall

January 10, 2019 — Aurobindo Pharma USA Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets USP and Valsartan Tablets USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. To date, Aurobindo Pharma USA Inc. has not received any reports of adverse events related to this recall.

The affected medications are indicated to control high blood pressure and for the treatment of heart failure. Patients who were prescribed Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.

The products subject to recall are listed on the U.S. Food and Drug Administration (FDA) website here. The product can be identified by checking the product name, manufacturer details and batch or lot number on the bottle containing these products.

The affected medications were distributed nationwide to Aurobindo Pharma USA Inc. wholesale, distributor, repackager and retail customers. Aurobindo Pharma USA Inc. is notifying its distributors and customers by phone and in writing to immediately discontinue distribution of the specific lots being recalled and to notify their sub-accounts. The company is arranging for return of all recalled products to Inmar/CLS Medturn. Instructions for returning recalled products are given in the recall letter.

Mylan Pharmaceuticals announced a recall of all lots of its products containing Valsartan in December. The affected products in that recall were manufactured by Mylan Pharmaceuticals Inc. and Mylan Laboratories Ltd., and distributed in the U.S. between March 2017 and November 2018.

For more information: www.fda.gov

Related Content

Abnormal Blood Pressure in Middle And Late Life Influences Dementia Risk

Image courtesy of the American Heart Association

News | Hypertension | August 20, 2019
In a study that spanned two and a half decades and looked at data from more than 4,700 participants, Johns Hopkins...
Blood Pressure Control Less Likely Among Those Treated in Low-income Areas
News | Hypertension | August 14, 2019
People enrolled in a large clinical hypertension management trial were half as likely to control their blood pressure ...
Pediatricians Assess How to Personalize Hypertension Treatment in Children
News | Hypertension | July 29, 2019
High blood pressure among children is on the rise and a lack of research about how to treat it has left pediatricians...
BackBeat Cardiac Neuromodulation Therapy Shows Immediate, Substantial Blood Pressure Reduction
News | Hypertension | June 04, 2019
Orchestra BioMed Inc. announced the presentation of two-year clinical data from the European Moderato I study of...
St. Bartholomew's Hospital Initiates CALM-2 Hypertension Trial
News | Hypertension | February 20, 2019
California-based Vascular Dynamics Inc. (VDI) is sponsoring a new clinical trial, called CALM-2 (Controlling And...
Research Sheds Light on Blood Pressure Drug Function
News | Hypertension | January 31, 2019
Researchers have mapped the active-state structure of the angiotensin II type 1 receptor, the target of widely...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Hypertension | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Barbershop Intervention Continues to Lower Blood Pressure at One Year
News | Hypertension | December 27, 2018
African-American men participating in a blood pressure reduction program implemented in barbershops continued to have...
Analytics 4 Life and Actelion to Develop New Diagnostics for Pulmonary Hypertension
News | Hypertension | December 14, 2018
Digital health company Analytics 4 Life and Actelion Pharmaceuticals Ltd. announced a collaborative agreement to...
Hypertensive Crisis Five Times More Likely Among Blacks, according to a late-breaking study at AHA 2018. #AHA #AHA18 #AHA2018
News | Hypertension | November 13, 2018
Black adults experience dangerous spikes in high blood pressure, called a hypertensive crisis, at a rate that is five...
Overlay Init